After back-to-back years of 20%-plus gains in 2023 and 2024, the S&P 500 is off to another strong start to 2025. However, the S&P 500's forward earnings multiple of 22 (as of Feb. 7) was also ...

We recently compiled a list of the Weak Earnings, Outlook Drag Shares of These 10 Firms on Thursday. In this article, we are ...

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

The Trump administration's decision to pause enforcement of an anti-bribery law raised the specter that drugmakers could ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Corbus Pharmaceuticals (CRBP – Research ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Royalty Pharma (RPRX – Research Report), ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

The grants have been the source of new treatments for cancer, heart disease, diabetes, strokes and H.I.V.; wonder drugs like ...

Mitsubishi Chemical Group has agreed to sell its pharmaceutical business to Bain Capital for more than $3 billion, in a bid to focus on its key chemical businesses. The Japanese chemical company said ...

Pharmaceutical manufacturers may need new models to maintain sustainable businesses and support patients who cannot afford ...